Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

NCT06781905 · clinicaltrials.gov ↗

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Cancer
Metastatic Lung Cancer With ALK/ROS1 Fusion

Interventions

OTHER: Assessments of neuropsychiatric, neurocognitive and psychosocial alterations

Sponsor

Hospices Civils de Lyon